Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

TB-4 Safe Side Effects: Research vs Clinical Comparison

The following table compares TB-4's side effect profile against two commonly researched regenerative peptides. BPC-157 and GHK-Cu. To provide context for how TB-4's safety margins compare within the broader peptide landscape. Injection Site Reactions 30–45% du

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • The following table compares TB-4's side effect profile against two commonly researched regenerative peptides. BPC-157 and GHK-Cu. To provide context for how TB-4's safety margins compare within the broader peptide landscape.
  • Injection Site Reactions
  • 30–45% during first 2 weeks, primarily mild erythema and subcutaneous nodules
  • 15–25%, generally milder and shorter duration
  • 10–15%, minimal unless using high copper concentrations
  • TB-4 produces the highest incidence of localized reactions due to actin remodeling mechanisms. Rotate injection sites and use smaller volumes to mitigate
  • Systemic Fatigue
  • 10–18% in first week, resolves within 14 days as metabolic adaptation occurs
  • <5%, rarely reported
  • <5%, occasionally reported with oral formulations
  • TB-4's energy reallocation effect is temporary but more pronounced than alternatives. Avoid combining with intensive training during first two weeks
  • Cardiovascular Effects
  • Measurable changes in ejection fraction in 18–23% of subjects; rare arrhythmia case reports
  • No documented cardiovascular effects in peer-reviewed literature
  • Minimal, though copper excess theoretically pro-oxidant
  • TB-4 is the only peptide in this comparison with documented cardiac effects. Baseline ECG recommended for subjects over 45 or with cardiovascular history
  • Gastrointestinal Symptoms
  • <10%, primarily mild nausea, dose-dependent
  • <5%, rare reports of altered bowel patterns
  • <5%, occasionally reported with high-dose oral copper
  • Lowest concern category across all three peptides. Symptoms resolve with dosage adjustment
  • Immune Modulation Concerns
  • Anti-inflammatory effects can prolong infection recovery; not recommended during active infections
  • Minimal immune suppression, some evidence of immune enhancement
  • No immune suppression documented
  • TB-4 requires timing consideration around infections. BPC-157 and GHK-Cu don't carry this constraint
  • Documented Serious Adverse Events
  • 2 case reports of transient arrhythmias in subjects with pre-existing cardiac conditions at doses >10mg weekly
  • None in peer-reviewed literature
  • TB-4's serious adverse event profile, while rare, is the only one documented in formal case reports among these three peptides

Related resources

More comparisons